MEBEVERINE

Posology One capsule of 200 mg twice daily, to be given one in the morning and one in the evening. Paediatric Population Mebeverine 200 mg modified release capsules are not recommended for use in children and adolescents below 18, due to insufficient data on safety and efficacy.

Duration of use is not limited. If one or more doses are missed, the patient should continue with the next dose as prescribed; the missed dose(s) should not be taken in addition to the regular dose. Special Population No posology studies in elderly, renal and/or hepatic impaired patients have been performed.

No specific risk for elderly, renal and/or hepatic impaired patients could be identified from available post-marketing data. No dosage adjustment is deemed necessary in elderly, renal and/or hepatic impaired patients.

Method of administration Adults (including the elderly):

The capsules should be swallowed with a sufficient amount of water (at least 100 ml water). 2).

The following adverse reactions have been reported spontaneously during postmarketing use. A precise frequency cannot be estimated from available data. Allergic reactions mainly but not exclusively limited to the skin have been observed.

Immune system disorders:

Hypersensitivity (anaphylactic reactions) Skin and subcutaneous tissue disorders: Urticaria, angioedema, face oedema, exanthema. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrose-isomaltese insufficiency should not take this medicine.

1.